World’s #1 Selling Contact Lens Brand ACUVUE®1 Brings Pioneering Innovation For Astigmatic Patients, Providing Visual Clarity And Comfort+2
The First^^ Toric Lens to have an Optimised Design according to Cylinder Power
Wokingham, UK, Sept. 04, 2025 (GLOBE NEWSWIRE) — Today, Johnson & Johnson, a global leader in eye health, announced the launch of a new product for astigmatic patients in UKI – ACUVUE® OASYS MAX 1-Day Contact Lenses for Astigmatism – the first contact lens to optimise toric design according to cylinder power to deliver on the complex needs of astigmatic patients.^^ The lens offers exceptional comfort,+2 clarity+2 and stability3 for astigmatic patients, with enhanced stability for patients with high astigmatism.3
Astigmatism affects about half of patients in at least one eye, making it one of the most common vision conditions.3 While a variety of contact lens options exist for astigmatic patients, many still face challenges – with one in four discontinuing lens wear in the first year due to issues such as blurred or poor vision and discomfort.4 Designed with modern life in mind, ACUVUE® OASYS MAX 1-Day Contact Lenses for Astigmatism offer optimal performance across the cylinder range3 for exceptional clarity+2 and comfort,+2 intended to deliver a personalised fit based on the amount of astigmatism. As digital device use continues to rise across all age groups, contributing to digital eye strain and dry eye symptoms, these lenses also help to empower patients to see comfortably amid evolving digital lifestyles.#2
Patients currently lead modern lifestyles with heavy digital device usage which can lead to digital eye strain and dry eye symptoms,5,6 impacting comfort across all ages. There is a need to design interventions focused to help preserve ocular surface health and associated well-being.
“We see a clear unmet need in astigmatism across the region, and our goal has been to grow our ACUVUE® OASYS MAX 1-Day portfolio to address it. With the introduction of this new toric lens, we’re proud to offer the first^^ contact lens with patient-centric design to meet specific astigmatic patient needs.^^ This reflects our deep commitment to delivering tailored solutions that provide exceptional all-day comfort,+2 clarity+2 and stability3 for patients as they navigate an increasingly digitally-demanding world, while empowering eye care professionals with a comprehensive set of tools to offer customised care,” said Jacqueline Henderson, President Vision EMEA, Johnson & Johnson.
Next-Generation Innovation Tailored for the Astigmatic Eye
ACUVUE® OASYS MAX 1-Day Contact Lenses for Astigmatism have been developed with a patient-centric design,3 enabling Eye Care Professionals to provide more tailored solutions for astigmatic patients. The enhanced design, supported by ACUVUE’s trusted Eye Inspired™ Innovations,¥Ω7 offers exceptional comfort,+2 clarity+2 and stability3 for patients.
Three powerful technologies are united to meet more astigmatic patient needs: ∫,3
- NEW CYLINDER OPTIMISED EYELID STABILISED DESIGN, to customise the slopes in the stabilisation zones across the cylinder range3
- TEARSTABLE™ TECHNOLOGY for optimised wetting distribution and prolonged tear film stability8,9,10
- OPTIBLUE™ LIGHT FILTER∫ to filter 60% of blue-violet light, minimising light scatter∫9
Clinical data shows strong fit performance, with 99% first lens fit success for ACUVUE® OASYS MAX 1-Day for Astigmatism.¶11 The efficient and streamlined fitting process may support more proactive fitting strategies, helping Eye Care Professionals introduce optimal lens options earlier in the consultation process that could better match patients’ visual and lifestyle needs.
“Many of my patients with astigmatism struggle with finding a contact lens that works for them, with existing options not addressing their needs – often having to choose between comfort and stability”, said Preete Kumar, Professional Affairs Consultant, Johnson & Johnson. “This new innovation from ACUVUE® offers tailored solutions based on the degree of a patient’s astigmatism, allowing me to meet my patients’ needs without compromise. It’s a meaningful step forward in delivering more customised, consistent care.”
ACUVUE® OASYS MAX 1-Day for Astigmatism
Featuring a combination of 3 powerful technologies,∫,2 this contact lens delivers exceptional comfort+2 and clarity+2 with enhanced stability for high cylinder patients.3 It has also shown proven performance across its key claims:2
- Nearly 99% of patients report being satisfied with overall vision++2
- 96% of patients report stable vision∏2
- Nearly 90% of patients report all-day comfort∏2
- 97% of patients report clear vision when driving at night##2
- 97% of patients report rarely or never experiencing eye fatigue#2
- 95% of patients report seeing comfortably when using a computerππ2
###
END
Important Safety Information: ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Contact lenses should not be used in case of eye infections or any other eye conditions, or in case of a systemic disease that may affect the eye. For detailed information, including contraindications, precautions and adverse reactions, please consult the Instructions for Use available on Johnson & Johnson website www.e-ifu.com.
For any additional information, please visit our Johnson & Johnson website www.jnjvisionpro.com/en-gb/.
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionising the way people see and experience the world. Visit us at Johnson & Johnson | Vision on LinkedIn.
About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalised. Johnson & Johnson Vision Care, Inc., is a Johnson & Johnson Company.
Cautions Concerning Forward-Looking Statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to ACUVUE® OASYS MAX 1-Day Contact Lenses for Astigmatism. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behaviour and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Footnotes
^Versus publicly available information for contact lenses for astigmatism as of July 2023
^^Versus publicly available information for contact lenses for astigmatism as of June 2025
∫ Filtering of HEV light by contact lenses has not been demonstrated to confer any systemic and/or ocular health benefit to the user. The Eye Care Professional should be consulted for more information
+T2B descriptive summaries: n ≥ 144
++ T2B descriptive summaries: n = 144
#T2B descriptive summaries: n = 349
## T2B descriptive summaries: n = 345
∏ T3B descriptive summaries: n = 144
ππT3B descriptive summaries: n = 349
¶ Criteria for first fit success: rotation ≤ 20 degrees, lens stability ≤ 5 degrees movement on blink; acceptable general fitting characteristics, no need for power or axis adjustment.
¥ Helps protect against transmission of harmful UV radiation to the cornea and into the eye.
Ω WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.
2025PP13250
References
1 Euromonitor International Limited; Eyewear 2026 edition; value sales at rsp, all retail channels, 2024 data; “ACUVUE® family of brands” represents aggregated sales of the following brands: 1-day ACUVUE®, ACUVUE® Oasys, ACUVUE® Vita, and ACUVUE®2.
2 JJV Data on file, 2024. Subjective Comparative and Descriptive Standalone Claims for ACUVUE® OASYS MAX 1-Day Contact Lenses for ASTIGMATISM.
3 Young G, Sully A, Hunt C. Prevalence of astigmatism in relation to soft contact lens fitting. Eye Contact Lens. 2011;37(1):20–25.
4 Sulley A, Young G, Hunt C. Factors in the success of new contact lens wearers. Contact Lens Anterior Eye. 2017 Feb;40(1):15-24.
5 Mereddy S, Gunnam RP, Karedla SR, Banerjee SK, Polaki S. Multifactorial analysis of dry eye syndrome: insights from Schirmer’s test, VDT exposure, and tear film stability. Int Ophthalmol. 2025 Jun 5;45(1):225.
6 Romeo MA, Coco G, Taloni A, Carnovale-Scalzo G, Scorcia V, Giannaccare G. Digital Applications for Videoterminal-Associated Dry Eye Disease. Vision (Basel). 2024 Nov 28;8(4):67.
7 JJV data on file 2024: ACUVUE® Brand – EYE-INSPIRED™ INNOVATIONS.
8 JJV Data on File 2022. TearStable™ Technology Definition.
9 JJV Data on File 2022. Effect on Tear Film and Evaluation of Visual Artifacts of ACUVUE® OASYS MAX 1-Day Family with TearStable™ Technology.
10 JJV Data on File 2022. Material Properties: 1-DAY ACUVUE® MOIST, 1-DAY ACUVUE® TruEye®, ACUVUE® OASYS 1-Day with HydraLuxe® Technology and ACUVUE® OASYS MAX 1-Day with TearStable™ Technology Brand Contact Lenses and other daily disposable contact lens brands.
11 Data on file 2024, ACUVUE® Brand Contact Lenses for ASTIGMATISM overall fitting success, orientation position, rotational stability and vision performance.
CONTACT: Media contact: Bryony Cox [email protected]
